Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 4/20 | 0.62 |
| ▸ | KDM1A | O60341 | 1/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA9 | Q16790 | 4/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | CA4 | P22748 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793673 | 0.86 | KEAP1 (0.76) | CA2CA1CA12CA9L3MBTL1 | |
| SCHEMBL1255246 | 0.81 | SMN1; SMN2 (0.53) | CA2CA1KDM1AMAOACA12 | |
| SCHEMBL21165326 | 0.81 | CA2 (0.66) | CA2CA1CA12CA9L3MBTL1 | |
| SCHEMBL15699779 | 0.81 | SMN1; SMN2 (0.57) | CA2CA1KDM1AMAOACA12 | |
| SCHEMBL3929043 | 0.79 | NAMPT (0.48) | CA2CA1KDM1AMAOACA12 | |
| SCHEMBL568013 | 0.79 | SMN1; SMN2 (0.50) | CA2CA1KDM1AMAOACA12 | |
| SCHEMBL13973174 | 0.78 | KEAP1 (0.69) | CA2CA1CA12CA9L3MBTL1 | |
| SCHEMBL18580 | 0.78 | NR3C2 (0.64) | CA2CA1CA12CA9L3MBTL1 | |
| SCHEMBL1751928 | 0.78 | SMN1; SMN2 (0.53) | CA2CA1KDM1AMAOACA12 | |
| SCHEMBL1255365 | 0.78 | CA9 (0.57) | CA2CA1KDM1AMAOACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288948-B1 | FUSED TRICYCLIC PYRAZOLE DERIVATIVES USEFUL FOR MODULATING FARNESOID X RECEPTORS | NOVARTIS AG (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NOVARTIS AG (CH) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351576-B2 | Fused tricyclic pyrazole derivatives useful for farnesoid X receptors | NR1H4, FXR1, GPBAR1 | CA2 2778/4885CA1 2880/4885KDM1A 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.